LivaNova (NASDAQ: LIVN) and Intersect ENT (NASDAQ:XENT) are both medical equipment, supplies & distribution – nec companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Institutional and Insider Ownership

86.0% of LivaNova shares are owned by institutional investors. Comparatively, 86.3% of Intersect ENT shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 13.7% of Intersect ENT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for LivaNova and Intersect ENT, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova 1 2 4 0 2.43
Intersect ENT 0 2 7 0 2.78

LivaNova currently has a consensus target price of $78.17, indicating a potential downside of 1.24%. Intersect ENT has a consensus target price of $33.43, indicating a potential upside of 1.76%. Given Intersect ENT’s stronger consensus rating and higher probable upside, analysts clearly believe Intersect ENT is more favorable than LivaNova.

Valuation & Earnings

This table compares LivaNova and Intersect ENT’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LivaNova $1.21 billion 3.14 -$62.78 million $3.75 21.11
Intersect ENT $78.71 million 12.30 -$25.22 million ($0.63) -52.14

Intersect ENT has lower revenue, but higher earnings than LivaNova. Intersect ENT is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LivaNova and Intersect ENT’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova 4.63% 9.33% 6.82%
Intersect ENT -19.81% -15.96% -14.16%

Summary

Intersect ENT beats LivaNova on 7 of the 13 factors compared between the two stocks.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Intersect ENT Company Profile

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with Analyst Ratings Network's FREE daily email newsletter.